Table 2. Distribution of clinical characteristics stratified by pretreatment GAR.
| Characteristic | GAR ≤0.58 | GAR >0.58 | P value |
|---|---|---|---|
| Patients | 135 | 181 | |
| Age (years) | |||
| Mean ± sd (range) | 60.2±10.7 | 63.0±11.6 | |
| <65/≥65 | 90/45 | 91/90 | 0.004 |
| Gender (female/male) | 44/91 | 55/126 | 0.676 |
| Smoke status (never/ever) | 66/69 | 69/112 | 0.056 |
| Histology (non-squamous/squamous) | 103/32 | 103/78 | 0 |
| Differentiation (well and moderate/poor) | 39/96 | 33/148 | 0.025 |
| TNM stage (III/IV) | 36/99 | 45/136 | 0.716 |
| Tumor stage (T1/T2/T3/T4) | 22/46/9/58 | 19/61/24/77 | 0.156 |
| Node stage (N0/N1/N2/N3) | 23/13/70/29 | 21/17/98/45 | 0.552 |
| Metastasis stage [none (M0)/regional (M1a)/distant (M1b)] | 36/36/63 | 45/44/92 | 0.763 |
| Metastasis organ (none/bone/brain/intra-lung/others) | 36/48/23/26/15 | 45/61/35/54/21 | 0.359 |
| Metastasis number (none/single/multiple) | 36/84/15 | 45/103/33 | 0.218 |
| Metastasis symptom (never/ever) | 94/41 | 117/64 | 0.352 |
| ECOG PS (≤1/>1) | 108/27 | 134/47 | 0.215 |
| Chemotherapy | 77 | 76 | |
| CR + PR + SD/PD | 58/19 | 59/17 | 0.737 |
TNM stage, Tumor-Node-Metastasis stage; ECOG PS, the Eastern Cooperative Oncology Group Performance Status Scale; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; GAR, globulin albumin ratio.